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ABSTRACT
Background and Objectives. To monitor and document the endemicity and disease
burden of acute hepatitis A in the area of an ongoing vaccine effectiveness study in
León, Nicaragua.
Methods. At community health centres in León, all children, adolescents and young
adults presenting with jaundice and/or other clinical signs of hepatitis were offered
free serologic screening (hepatitis A, B and C) and blood tests for liver enzymes
and bilirubin. Clinical and socioeconomic data were collected with a structured
questionnaire. Diagnosis of acute hepatitis A was confirmed by anti-HAV IgM testing.
Using logistic regression we compared the characteristics and living conditions of acute
hepatitis A cases with those of non-cases.
Results. Of 557 eligible subjects enrolled between May 2006 and March 2010, 315
(56.6%) were diagnosed with hepatitis A, 80.6% of them ≤10 years and five >18 years
of age. No severe cases were encountered. Apart from jaundice (95.6%) and other signs
of hepatitis A (fever, pale stool, dark urine, nausea, vomiting, anorexia), two thirds of
patients hadmoderately raised liver enzymes. Cases occurred throughout the year, with
highest incidences from August to March. Poor sanitary conditions and crowding were
the main risk factors.
Conclusions. In the study area, hepatitis A is still highly endemic in young and
school age children living in low socioeconomic conditions. There are, however, first
indications that the endemicity level is shifting from high to high-intermediate.
Subjects Epidemiology, Gastroenterology and Hepatology, Infectious Diseases, Internal Medicine
Keywords Hepatitis A, Clinical features, Serology, Epidemiology, Risk factors, Seasonality,
Central America
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INTRODUCTION
The hepatitis A virus (HAV) is mainly transmitted by the fecal-oral route (World Health
Organization, 2010a). Therefore, the burden of disease correlates with the quality of
sanitary conditions, the access to clean water and the socioeconomic status (Jacobsen &
Koopman, 2005). After an incubation period of 14 to 50 days the disease might start with
unspecific symptoms such as malaise, fatigue, anorexia, vomiting, abdominal discomfort
and diarrhea. In the course of symptomatic illness, which ensues more often in older
children and adults, dark urine, pale stool and jaundice can also be observed; in children
below 6 years of age less than 10% show jaundice (Armstrong & Bell, 2002). Rarely,
fulminant hepatic failure develops, associated with a severe disease process and a high case
fatality, usually necessitating liver transplantation (Lemon et al., 2018). Interestingly, HAV
has been reported to be a major cause for fulminant hepatic failure in children in Pakistan
(Talat et al., 2020) and Latin America (Ciocca et al., 2007).
There are many unreported cases of hepatitis A (up to 80% of infections). WHO
estimated from 1990 to 2005 an increase in the number of infections and deaths due
to hepatitis A from 177 to 212 million and 30,283 to 35,245, respectively (World Health
Organization, 2010a). From the 212 million infections only 33 million cases are estimated
to present as symptomatic illness (Rein et al., 2014). Different studies showed over the last
two decades, however, decreasing hepatitis A seroprevalences all over the world, except for
Africa, most likely due to better access to clean water, better sanitary conditions, higher
educational level and less crowded housing conditions (Jacobsen & Wiersma, 2010). Levels
of hepatitis A endemicity are defined on the basis of seroprevalence: ‘‘high (≥ 90% by age
10 years); intermediate (≥ 50% by age 15 years, with <90% by age 10 years); low (≥ 50%
by age 30 years, with <50% by age 15); and very low (<50% by age 30 years)’’ (Jacobsen
& Wiersma, 2010). Because HAV infection leads to lifelong immunity there are in high
endemic settings hardly any susceptible adults, and clinically manifest HAV infections
are rare. However, if sanitary conditions improve, there will be a shift to intermediate
endemicity, and with increasingly older age groups remaining susceptible, more severe
cases (World Health Organization, 2010a) and outbreaks (Bell et al., 1998) will be observed.
For Nicaragua there exist very few published data on the hepatitis A epidemiology (Andani
et al., 2020). Hepatitis A infections are not routinely reported by the health authorities in
Nicaragua, a still highly endemic country with 36.9 cases per 100,000 inhabitants reported
for 2012 (Supplemental File 4).
Universal mass vaccination (UMV) of toddlers with a two-dose regimen is now
recommended by WHO for countries with sizable acute hepatitis A incidences and
declining endemicity (World Health Organisation, 2012). Two-dose UMV successfully
eliminates hepatitis A within a few years, as shown, e.g., in Israel (Levine et al., 2015).
Single-dose UMV likewise lowers rapidly the disease burden, as documented for Argentina
(Vizzotti et al., 2014) and Brazil (Souto, de Brito & Fontes, 2019). Although single-dose
vaccination elicits in >95% of children seroprotection for at least 7–10 years (Mayorga et
al., 2016; Urueña et al., 2016; Espul et al., 2020), the long-term protective effectiveness over
20-30 years remains still to be established.
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The objectives of our project were: (1) to document with a prospective survey (2006–
2010)—in parallel to an ongoing single-dose vaccine effectiveness study (Mayorga et al.,
2016)—the sustained circulation of HAV in León, Nicaragua; (2) to describe the clinical
features of acute hepatitis A; and (3) to evaluate the HAV infection risk factors in the
same study area, for which already for the 1990s and the 2000s a high endemicity had been
reported (Mayorga Perez et al., 2014).
MATERIALS & METHODS
Study conduct
A viral hepatitis diagnosis survey was conducted from May 2006 to June 2010 to
document—among others—the continuing circulation of HAV in the study area of a
concurrent single-dose hepatitis A vaccine trial (Mayorga et al., 2016). The survey was set
up by the Medical Faculty of the National Autonomous University (UNAN) in León to
capture children, adolescents and adults with clinical hepatitis. During the study period
regular advertisements were made in the local radio program. Everyone who presented
symptoms suggestive for acute hepatitis, such as jaundice, fever, vomiting, nausea, etc.
was encouraged to visit one of the community health centers in order to have his/her
illness assessed for free. Reporting patients were asked if they would agree to participate
in the study, which consisted—apart from answering a questionnaire—only in taking of a
single blood sample (5–7 ml). These patients were thus offered a free serologic screening to
establish the viral etiology (hepatitis A, B or C), as well as free blood tests for liver enzymes
and bilirubin. The presence of diagnostic anti-HAV IgM antibodies was later confirmed
at the Technical University, Munich, Germany. The study was a community-based survey
and no specific inclusion or exclusion criteria were applied.
The project was approved by the Medical Faculty of the UNAN, León. Written informed
consent was obtained from participating patients and in case of children/adolescents from
their parents or guardians.
Questionnaire
The questionnaire comprised questions on clinical features and demographic characteristics
(age and sex), as well as on socioeconomic conditions like crowding (number of rooms and
people per household), location of the main water source and the toilets, and some data
regarding education and work. Symptoms (anorexia, nausea, vomiting, fever, malaise) and
clinical signs (jaundice, pale stool, dark urine) were solicited and documented. The days
from start of symptoms until presentation at the health centers and the history of a recent
blood transfusion were also noted.
Laboratory evaluation
Screening of serum samples for anti-HAV IgM (as for Hepatitis B and Hepatitis C) was
done daily at the clinical microbiology laboratory of the Medical Faculty of UNAN León,
using the enzyme immunoassay (EIA) stripe test kit ImmunoComb II fromOrgenics, Israel.
The sera were stored at −20 ◦C and later shipped to the Institute of Virology, Technical
University, Munich, Germany, for confirmative analysis of anti-HAV IgM antibodies
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(CDC, 2020), using the microparticle EIA HAVAB-M 2.0 for the AxSYM system, Abbott
Laboratories, USA. The following Index reference values (anti-HAV-IgM content) were
used: <0.80: non-reactive test, acute hepatitis A excluded; 0.80–1.20: gray-zone, possibly
recent recovery from acute HAV infection; >1.20: reactive, indicating acute HAV infection
(Frösner G., personal communication). ‘‘Gray-zone’’ results were counted as no hepatitis
A.
Quantitative analysis of blood samples for total anti-HAV (IgG+IgM) antibodies were
made at the same laboratory, using the microparticle EIA HAVAB 2.0 Quantitative for
AxSYM, Abbott Laboratories, USA. A result of≥20 mIU/mL was defined as seroprotective
(CDC, 2020), with a lower limit of detection of 10 mIU/mL.
Reference normal values for GPT were ≤40U/l for men and ≤32U/l for women using
the GPT (ALT)-LQ test. For GOT they were≤38U/l for men and≤31U/l for women, using
the GOT (AST)-LQ test. Total bilirubin values were considered normal up to 1.10 mg/dl,
using the BILIRUBIN T-DMSO test. All tests were from SPINREACT, S.A./S.A.U, Spain.
Statistical methods
For the descriptive analysis of categorical characteristics of acute hepatitis A cases and
non-cases we calculated the chi-square statistics and p-values for the null hypothesis of
difference in distribution of categories. Univariable and multivariable logistic regression
analysis was used to assess associations of possible risk factors for being a hepatitis A case,
such as excreta disposal, water source (yes vs. no), crowding (>2.5 persons per room in
a given household vs ≤2.5), age groups and sex. From the logistic regressions we report
Odds Ratios and 95% confidence intervals (CIs). We also calculated the geometric mean
concentrations (GMCs) with 95% CIs for the total anti-HAV antibodies. For values <10
mIU/ml, a value of 5 mIU/ml was used for the GMC calculation. A p-value <0.05 was
considered as significant. Statistical Software R (4.0.3) was used for the statistical analyses.
RESULTS
Study population
A total of 575 children, adolescents and adults with suspected viral hepatitis were screened
fromMay 2006 until June 2010. Eighteen patients had to be excluded from analysis: samples
lost (n= 2), anti-HAV IgM serology for April-June 2010 samples lacking (n= 15) or unclear
age (n= 1), thus leaving 557 eligible patients (see Study Flow Chart, Fig. 1). Six patients
had ‘‘gray-zone’’ results of the anti-HAV IgM test and were counted as non-hepatitis A.
The majority (80.6%) of the 315 patients with acute hepatitis A were children ≤10 years of
age, two were ≤1 year and five >18 years old (Table 1). With this cohort of acute hepatitis
A cases we documented the continuous exposure to HAV of the subjects enrolled into the
single-dose hepatitis A vaccination trial carried out by our team in the same area during
2005–2012 (Mayorga et al., 2016).
We did not evaluate occupation and educational levels because the vast majority of study
subjects were very young or school age children and thus an analysis of these parameters
would not have made sense.
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Figure 1 Study flowchart.
Full-size DOI: 10.7717/peerj.11516/fig-1
Seroprevalence and antibody levels
Quantitative anti-HAV IgG+IgM measurements could only be done in 166 of the 315
hepatitis A cases (data not shown) and in 94 of the 242 cases without hepatitis A (Table 2).
All patients with acute hepatitis A had high anti-HAV antibody concentrations, with
minimum and maximum levels of 1,485 mIU/ml and 181,000 mIU/ml, respectively.
Eighty-three (88.3%) of the 94 non-hepatitis A patients had protective levels of anti-HAV
antibodies (min 62 mIU/ml –max 209,900 mIU/ml), representing past HAV infection.
Three of the 5 children aged≤1 year had protective levels of maternal anti-HAV antibodies
of 258, 341 and 6,173 mIU/ml, respectively, and 2 were anti-HAV negative. The non-
hepatitis A cases aged 1-≤6 years, 6-≤11 years and the >11 years old subjects had had
hepatitis A in the past in 68.8%, 89.5% and 96.3%, respectively. Among the subjects >11
years of age only two young adults aged 18 and 19 years were anti-HAV antibody negative.
Only 3 and 8 of the 557 patients were screened positive (IgM antibodies) for acute hepatitis
B and acute hepatitis C, respectively. These cases were not further investigated within this
project.
Clinical features
For 15 patients the start of symptoms was unclear or missing. 56.8% of the remaining
542 patients presented themselves within 5 days after falling ill and one quarter after 6 to
11 days. Among the 89 patients presenting later than 11 days there were proportionally
less cases of hepatitis A, i.e., 37.1% as compared to 62.9%. The leading hepatitis A feature
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Table 1 Characteristics of the study population.







≤1 year 2 (0.6) 16 (6.6)
1–≤5 years 70 (22.2) 47 (19.4)
5–≤10 years 182 (57.8) 64 (26.4)
10–≤14 years 46 (14.6) 32 (13.2)
14–≤18 years 10 (3.2) 11 (4.5)
>18 years 5 (1.6) 72 (29.8)
Sex 1.000
female 157 (49.8) 120 (49.6)
male 158 (50.2) 122 (50.4)
Socioeconomic
Housing 0.013
no crowding 141 (44.8) 135 (55.8)
crowding 174 (55.2) 107 (44.2)
Toilets 1.000
outside 157 (49.8) 99 (40.9)
inside 158 (50.2) 143 (59.1)
Water 0.044
outside 57 (18.1) 43 (17.8)
inside 258 (81.9) 199 (82.2)
Clinical features
Jaundice <0.001
no 14 (4.4) 48 (19.8)
yes 301 (95.6) 194 (80.2)
Pale stool <0.001
no 207 (65.7) 203 (83.9)
yes 108 (34.3) 39 (16.1)
Dark urine <0.001
no 120 (38.1) 162 (66.9)
yes 195 (61.9) 80 (33.1)
Nausea <0.001
no 83 (26.3) 98 (40.5)
yes 232 (73.7) 144 (59.5)
Vomiting 0.001
no 81 (25.7) 127 (52.5)
yes 234 (74.3) 115 (47.5)
(continued on next page)
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Table 1 (continued)






no 64 (20.3) 72 (29.8)
yes 251 (79.7) 170 (70.2)
Anorexic 0.004
no 55 (17.5) 68 (28.1)
yes 260 (82.5) 174 (71.9)
Malaise 0.101
no 46 (14.6) 49 (20.2)
yes 269 (85.4) 193 (79.8)
Laboratory finding *
Liver enzymes GOT <0.001
elevated 281 (89.2) 108 (44.6)
normal 34 (10.8) 134 (55.4)
Liver enzymes GTP <0.001
elevated 289 (91.7) 93 (38.4)
normal 26 (8.3) 149 (61.6)
Total serum bilirubin <0.001
elevated 274 (87.0) 118 (48.8)
normal 41 (13.0) 124 (51.2)
Notes.
*cut-off definitions are described in the Methods section.
Table 2 Anti-HAV IgG antibody levels of subgroup of patients (n= 94) without hepatitis A.
Patients tested Anti-HAV IgG antibody concentrations
(mIU/mL)
Seroprotection**
n = 94 GMC* (95% CI) Min/max n (%)
Age
≤1 year 5 106.3 (2.4; 4,719.9) <10/6,173 3 (60.0)
1–≤6 years 16 965.6 (111.7; 8,345.2) <10/209,900 11 (68.8)
6–≤11 years 19 8,267.6 (1,889.9; 36,167.4) <10/147,100 17 (89.5)
11–≤16 years 13 10,568.9 (5,178.7; 21,569.4) 989/50,380 13 (100.0)
16–≤20 years 7 1,004.6 (30.8; 32,751.5) <10/32,300 5 (71.4)
20–≤25 years 9 11,990.0 (6,557.8; 21,921.8) 3,529/29,050 9 (100.0)
>25 years 25 5,487.8 (3,468.7; 8,682.1) 602/34,150 25 (100.0)
Notes.
GMC: geometric mean concentration; CI: confidence interval.
*For <10 mIU/ml a value of 5 mIU/ml was used for the GMC calculation.
**Seroprotection: ≥20 mIU/mL of anti-HAV IgG antibodies.
was jaundice. Of all 557 patients with assumed viral hepatitis 495 (88.9%) had jaundice,
301 (95.6%) among the acute hepatitis A patients and 194 (80.2%) among the non-A
cases (p< 0.001) (Table 1). From the 62 cases without jaundice only 14 (22.6%) had
acute hepatitis A. Hepatitis A patients had significantly (p< 0.001) more of the following
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solicited symptoms and signs, than non-A patients: 34.3% vs. 16.1% pale stool, 61.9% vs.
33.1% dark urine, 73.7% vs. 59.5% nausea, and 74.3% vs. 47.5% vomiting. Rates of 79.7%
vs. 70.2% were found for fever (p= 0.014), and 82.5% vs. 71.9% for anorexia (p= 0.004).
Only the difference for malaise (85.4% vs. 79.8%) was not significant (p= 0.101) (Table 1).
Having had a blood transfusion was more often recorded in subjects without hepatitis A
(5.4% vs. 1.3%, p= 0.011), probably a chance finding due to the small numbers (n= 17).
Laboratory findings (biochemistry)
Serum liver enzymes (GOT, GPT) and total serum bilirubin were all significantly
(p< 0.001) more often elevated in hepatitis A than in non-A patients (Table 1). The
highest values were 2920 U/l for GPT, 2750 U/l for GOT and 43.2 mg/dl for total bilirubin.
According to the staff of the health centers none of the study patients developed a more
severe pathology later on.
Sociodemographic factors
The odd ratio (OR) for contracting hepatitis A was for children aged 5-≤10 years 2.49
(crude) and 2.45 (adjusted), respectively, and then declined with age to 0.06 (crude) and
0.06 (adjusted), respectively, in the patients aged >18 years (Table 3). Logistic regression
did not change these values for the age groups, the p-value stayed significant with <0.001.
Significantly less cases of acute hepatitis A were found in children from >10 years onwards.
This fact was independent from other sociodemographic factors. The OR for having a
toilet inside the house was 0.7 (crude) and 0.75 (adjusted), respectively, with p-values
of 0.036 (crude) and 0.191 (adjusted), respectively, however, no longer significant after
logistic regression. The place of the toilet was a factor probably influenced by other
hygiene conditions and/or sex and age and was thus not an independent risk factor. OR
for ‘crowding’ was 1.56 (crude) and 1.1 (adjusted), with p-values of 0.01 (crude) and 0.62
(adjusted), respectively; thus, also crowding was not found to be an independent risk factor
(Table 3). Logistic regression analyses were also made for the combinations of age groups
and crowding, age groups and water source, localization of toilet and sex, and again no
significant findings were seen and no differences could be observed (data not shown).
Seasonality
All along the observation period May 2006 to June 2010 cases of suspected viral hepatitis
were enrolled (∼11.1/month), with slightly more patients presenting themselves at the
health centers in the 1st and 3rd quarters of the year (data not shown). 56.6% of suspected
cases were diagnosed with acute hepatitis A (∼6.7/month). On average, more cases of acute
hepatitis A were diagnosed in the 4th and 1st quarters (autumn & winter) than in the 2nd
and 3rd quarters (Fig. 2). The percentage of hepatitis A cases among all persons examined
decreased from 63.5% (n= 54/85) in 2006 to 50.0% (n= 32/64) cases in 2010 (p= 0.013,
p for trend = 0.0016). The age distribution of patients with acute hepatitis A remained,
however, similar over the years (data not shown).
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Female 277 157 (56.7) 1.0 (ref) 1.0 (ref)
Male 280 158 (56.4) 0.99 (0.71–1.38) 0.97 (0.66–1.42) 0.953 0.872
Age
0–≤5 years 135 72 (53.3) 1.0 (ref) 1.0 (ref)
5–≤10 years 246 182 (74.0) 2.49 (1.6–3.88) 2.45 (1.57–3.84)
10–≤14 years 78 46 (59.0) 1.26 (0.72–2.22) 1.27 (0.72–2.25)
14–≤18 years 21 10 (47.6) 0.8 (0.31–2.01) 0.8 (0.31–2.04)
>18 years 77 5 (6.5) 0.06 (0.02–0.15) 0.063 (0.02–0.15) <0.001 <0.001
Housing
No crowding** 276 141 (51.1) 1.0 (ref) 1.0 (ref)
Crowding 281 174 (61.9) 1.56 (1.11–2.18) 1.1 (0.75–1.62) 0.01 0.62
Toilets
Outside*** 256 157 (61.3) 1.0 (ref) 1.0 (ref)
Inside 301 158 (52.5) 0.7 (0.5–0.98) 0.75 (0.48–1.15) 0.036 0.191
Water
Outside**** 100 57 (57.0) 1.0 (ref) 1.0 (ref)
Inside 457 258 (56.5) 0.98 (0.63–1.51) 1.41 (0.82–2.42) 0.921 0.209
Notes.
N, patients enrolled with suspected viral hepatitis; n, patients with acute hepatitis A; OR, Odds Ratio; CI, confidence interval; ref, reference group.
*Adjusted for: sex, age, housing, toilets and water.
**CROWDING defined as >2.5 persons/room.
***TOILET outside = outside or latrine.
****WATER outside= water from a well.
Figure 2 City of León: seasonality of symptomatic hepatitis A cases 2006–2010.Monthly numbers of
enrolled symptomatic hepatitis A cases by years (2006 –2010); thick gray line represents median number
of cases per month.
Full-size DOI: 10.7717/peerj.11516/fig-2
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DISCUSSION
Study population: In our study 80.6 of the 315 symptomatic hepatitis A cases enrolled
were children aged≤10 years, an age where HAV infection is in the majority asymptomatic
(Armstrong & Bell, 2002). This implies that many more subclinical HAV infections must
have occurred in parallel in the population surveyed. Overall, our findings indicate that
Nicaragua was in 2006–2010 still a country of high endemicity and that the single-dose
hepatitis A vaccination study (Mayorga et al., 2016)—for which the present project acted as
a kind of community control group—had been conducted during a sustained circulation
of HAV.
Seroepidemiology : Quantitative anti-HAV IgG antibody levels could only be measured
in 263 of the 557 patients with suspected hepatitis. In the Non-A subpopulation tested
(n= 94), the age-specific seroprotection rates rise until the age of 11- ≤16 years, where
100% seroprotection is reached (Table 2), consistent with the 100% found from age
18 years onwards in our 2003 study (Mayorga Perez et al., 2014). The present anti-HAV
antibody data cannot be used as cross-sectional population seroprevalence data, as only
symptomatic subjects were screened. However, the data gathered allow the conclusion that
hepatitis A was still highly endemic in the area investigated: nine of the 11 Non-A patients
lacking seroprotection were ≤11 years of age and only two were 18 and 19 years of age.
Nevertheless, the incomplete seroprotection of 71.4% observed in the age group 16 to ≤20
years, and the fact that two of the five Non-A infants were seronegative, i.e., their mothers
most likely as well, indicates the beginning of a transition away from high endemicity. The
most recent hepatitis A data cover the years 2004–2012 and report for the whole country
a rise from 19.2 to 36.9 infections per 100,000 inhabitants, and for León a rise from 12.6
to 22.2 (2011), followed by a sharp increase to 86.9/100.000 in 2012 (Supplemental File 4).
Our monthly enrolment of an average 6.7 patients with acute hepatitis A matches well with
the average of 6.3 cases reported monthly for León during 2006–2010 (Supplemental File
4). Using our 2003 cross-sectional serosurvey data (Mayorga Perez et al., 2014), a recent
literature review on hepatitis A epidemiology in Latin American countries classified the
endemicity level of Nicaragua as high-intermediate (Andani et al., 2020), based on the
age at midpoint of population immunity (Mohd Hanafiah, Jacobsen & Wiersma, 2011)
of 5–9 years. Previous studies in the same area in León showed that there was already
between 1995–96 and 2003 a halving of the HAV infection risk for 1 to 5 years old children
(Mayorga Perez et al., 2014). Although we found with the limited serosurvey data only
few serological indications of shifting endemicity among the non-A cases, i.e., very few
HAV susceptible school children or young adults (Table 2), 17.8% of the acute hepatitis
A cases occurred between 10 and ≤18 years (n= 56) and 1.6% (n= 5) at >18 years of
age. In addition, there were two cases in infants who are in hyperendemic settings usually
seroprotected by maternal antibodies (Brinkhof et al., 2013). Taken all together, these signs
of a beginning epidemiological shift are a call for the health authorities to start monitoring
hepatitis A more closely, e.g., with repeated cross-sectional serosurveys (Cutts & Hanson,
2016; Mayorga Perez et al., 2014), in order to not miss the right time to start with public
health interventions, such as e.g., universal childhood vaccination.
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Clinical features: The clinical outcome of HAV infection is strongly associated with age:
below 6 years of age only 10–20% of infections are symptomatic, at the age of 10 years
up to 50% might present jaundice or other clinical features and from age 18-20 years
upwards 80–90% of infections are symptomatic (Armstrong & Bell, 2002). The severity of
disease and fatal outcomes are higher in older age groups, with case fatality rising from
0.1% in children <15 years, to 0.3% among persons 15–39 years of age and reaching
1.8–5.4% above 50 years of age (Lemon et al., 2018). In our study, no severe cases were
seen, the laboratory findings were ‘unspectacular’ and corresponded to the overall mild
clinical features of the patients enrolled. None of the children or adolescents had to be
hospitalized, which is typical for a country where hepatitis A is highly endemic and most
infections occur during childhood (World Health Organization, 2010a). However, there are
reports from Latin American countries of severe cases with fulminant hepatitis A and acute
liver failure (Ciocca et al., 2007; Ferreira et al., 2008), this being an important reason for
implementation of UMV of children (Lemon et al., 2018), as e.g., in Argentina (Vizzotti et
al., 2014). It is still debated whether differences between various geographic world regions
regarding pathogenicity and virulence of HAV are due to genetic host factors in certain
ethnic groups or due to nucleotide sequence variations in certain HAV subtypes (Long et
al., 2014; Vaughan et al., 2014).
Socioeconomic factors: All over the world the risk of HAV infection is highly correlated
with the socioeconomic status (Jacobsen & Koopman, 2005). Although the global number
of HAV infections is still on the rise (World Health Organisation, 2012)), declining risks
of infections are seen in many countries over the last two decades, mainly due to rising
sanitary and economic standards and better access to clean water (Jacobsen & Koopman,
2005), but in some countries also due to UMV, such as in Israel (Levine et al., 2015),
Argentina (Vizzotti et al., 2014) and Brazil (Souto, de Brito & Fontes, 2019). This shift from
high to intermediate HAV endemicity has been observed in Latin America since the
1990s, a trend which continued in the 2000s (Jacobsen & Wiersma, 2010; World Health
Organization 2010b; Andani et al., 2020). The risk for HAV infection is influenced by many
different factors. Logistic regression analysis showed in Brazil that anti-HAV seroprevalence
correlates with increasing age and level of crowding (Vitral et al., 2014), whereas access
to clean water and reinforced concrete buildings were protective factors (Vitral et al.,
2012). For age and crowding we can see similar effects in our study, with age being the most
strongly correlated factor. For the water source we saw no significant effect, even though this
is mentioned in many studies from Latin America (Jacobsen & Wiersma, 2010), probably
due to fact that the water was clean in our study area, even if it came from an outside well.
In a Brazilian study, an overall low socioeconomic status was identified as risk factor (Vitral
et al., 2012). We could not assess this in our study, because we did not evaluate income
and education of the families. Thus, the socioeconomic risk factors for HAV identified
in our study were only the sanitary conditions, i.e., the place of the toilet, and crowding.
Household contacts are an important source of infection (Lima et al., 2014). In our setting,
crowding made a significant difference in crude Odds ratios but not in the adjusted ones.
Also, we could not see a difference between households hosting different age groups.
Another Brazilian study suggests that crowding is confounded by other socioeconomic
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factors, possibly due to the difficulty in maintaining hygiene in big households (Almeida
et al., 2001). In our study this is shown with the adjusted odds ratio, where the p-value for
crowding is no longer significant, indicating that there is a confounding by socioeconomic
factors, such as the localization of toilets (Table 3). In the logistic regression analysis we
saw a correlation between the different risk factors. Independently seen, none of the factors
made, however, a significant difference. Therefore, the main risk factor appears to be the
low socioeconomic status with all his features.
Seasonality : In our study there were slightly more hepatitis A cases in the 1st and 4th
quarter of the year, i.e., during autumn/winter, when the weather is in Nicaragua slightly
cooler and drier. There are seemingly conflicting data published on hepatitis A seasonality,
some reports indicating peak incidences in the wet season or summer, as for Brazil (Villar,
de Paula & Gaspar, 2002), others in the dry season or winter, as in Israel (Green et al.,
2001). Many different environmental factors, such as rainfall, ambient temperature, and
air humidity, as well as host behavior, source of infection and mode of transmission are
playing a role in the seasonality of infectious diseases (Martinez, 2018). A recent review on
the seasonality of viral hepatitis explains these seemingly conflicting seasonality patterns for
hepatitis A infections with the different modes of transmission being decisive: water-borne
during wet summer seasons in case of low hygiene standards and rather food-born in
winter, caused e.g., through shellfish consumption (Fares, 2015). Interestingly, even in
present-day Spain water-related climate events correlate with the incidence of hepatitis A
(Gullón et al., 2017).
Our study has limitations: The data collection was done via passive surveillance, relying
on self-reporting of cases (parents/patients). The real number of acute hepatitis A cases
was most likely higher, as we collected the more symptomatic cases, and because of the low
manifestation index in young children, many more asymptomatic HAV infections must
have occurred during the observation period. We collected educational levels and jobs
only for the enrolled subjects themselves, and not for their mothers/parents, which would
have made more sense because most of the patients were young children. Anti-HAV IgG
antibody data were only available for 47% of all 557 cases of assumed viral hepatitis and in
only 94 of the 242 Non-A cases, limiting the significance of the age-specific seroprotection
data, although they pretty well match previous data from the same area (Mayorga Perez
et al., 2014). The number of 315 hepatitis A cases was too small to assess in the given setting
with certainty the influence of all socioeconomic factors on contracting acute hepatitis A.
The strengths of the study were: In a hepatitis A endemic setting, a large series of cases
with assumed viral hepatitis was carefully ascertained and laboratory confirmed, allowing
to accurately describe the clinical features of hepatitis A. Due to the prospective collection
of viral hepatitis cases over all seasons of 4 years, the seasonality features of hepatitis A
could be assessed and documented for the first time for Nicaragua. The screening test
diagnosis of acute hepatitis A was confirmed by a recognized reference laboratory.
CONCLUSIONS
Nicaragua is a country of still high hepatitis A endemicity, with all its typical features.
The majority of cases were oligosymptomatic with no severe pathology seen in over three
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hundred documented cases. The main risk factor for acquiring hepatitis A is living in low
socioeconomic conditions. There are some first indications that the endemicity level started
in the 2000s shifting from high to high-intermediate. A closer monitoring of hepatitis A is
warranted in Nicaragua in order to be able to start in time with appropriate public health
interventions.
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